https://www.zonebourse.com/cours/action/AIM-IMMUNOTECH-INC-65218228/actualite/AIM-ImmunoTech-Inc-acheve-le-traitement-du-dernier-sujet-de-l-etude-de-phase-2-evaluant-Ampligen-45410491/?utm_source=telegram&utm_medium=social&utm_campaign=share